cellular biomedicine group
CBMG Expands CAR-T And Stem Cell Facilities
Cellular Biomedicine Group has expanded its facility in Huishan High Tech Park to increase the company’s capacity for CAR-T and stem cell products.
CMBG Receives US$2.29 Million Grant For Stem Cell Therapy
China's Cellular Biomedicine Group has received US$2.29 million to support pre-clinical studies of stem cell therapy for knee osteoarthritis.
Dangdai Invests Over US$43 Million In CBMG
Dangdai's investment in CMBG will help further long-term clinical trials for stem cell therapies and chimeric antigen receptor T-cell trials for selected cancers.
Yao Yihong Appointed CBMG CSO
Dr. Yao Yihong has been appointed as CBMG's chief scientific officer to lead research programs in immuno-oncology and autoimmune/inflammatory diseases.
CBMG Acquires CD40LGVAX Technologies
Building on positive Phase I results, the CD40LGVAX vaccine will undergo further trials in the second half of 2015.
CBMG Expands Beijing GMP Facility
CBMG will open a third GMP facility in Beijing to develop their immunotherapy platform, CAR-T.
CBMG Raises US$19.6 Million With Private Placement Offering
The proceeds raised will be used to advance clinical trials of CBMG's lymphoma drugs and therapeutic platforms.
CBMG Acquires Novel T-Cell Therapy Technology
The CAR-T cell therapy developed at the Chinese People's Liberation Army General Hospital uses cancer patient's own immune cells to attack tumors.
Agreen Acquisition Enhances CBMG’s T-Cell Portfolio
China's Cellular Biomedicine Group acquires Agreen for US$3.38 million in cash in addition to stock units.
China’s CBMG Begins Trading On NASDAQ
Cellular Biomedicine Group, which develops cell therapeutics targeted at the Chinese market, has listed on NASDAQ.
